Skip to main content
. 2017 Jul 28;12(7):e0182166. doi: 10.1371/journal.pone.0182166

Fig 5. Evaluation of the cytotoxicity of PKM2-inhibitor administration in mice.

Fig 5

(A) H&E and IHC stains of mouse tumors following shikonin treatment. (B) Shikonin treatment did not cause apparent pathologic abnormalities in the brain, kidney, liver, or heart according to H&E staining. H&E, hematoxylin and eosin; IHC, immunohistochemistry; PKM2, Pyruvate kinase M2.